NYSE$PFE
Pfizer · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Pfizer reported strong third-quarter results, driven by focused commercial execution and robust double-digit revenue growth across the product portfolio. The company raised full-year 2024 revenue and adjusted diluted EPS guidance.
Pfizer reported a strong third quarter in 2024, marked by a 32% year-over-year operational revenue increase to $17.7 billion. Excluding Paxlovid and Comirnaty, revenues grew 14% operationally. The company raised its full-year revenue guidance to $61.0 to $64.0 billion and adjusted diluted EPS guidance to $2.75 to $2.95.
- Third-quarter revenues reached $17.7 billion, a 32% operational increase year-over-year.
- Excluding Paxlovid and Comirnaty, revenues grew 14% operationally.
- Reported diluted EPS was $0.78, and adjusted diluted EPS was $1.06.
- Full-year revenue guidance raised to $61.0 to $64.0 billion, and adjusted diluted EPS guidance raised to $2.75 to $2.95.
Headline financials
Revenue & EPS history
Pfizer · Revenue · Quarterly
$17.7B
Revenue by segment
Pfizer · $12.9B total across 1 segment · Q3 2023
- Biopharma$12.9B-42.1%100.0%
Forward guidance
Pfizer raised its full-year 2024 revenue guidance to a range of $61.0 to $64.0 billion and adjusted diluted EPS guidance to a range of $2.75 to $2.95.
Tailwinds
- Revenue guidance increased by $1.5 billion at the midpoint.
- Adjusted diluted EPS guidance increased by $0.30 at the midpoint.
- Revenue guidance includes approximately $10.5 billion in anticipated revenues for Comirnaty.
- Revenue guidance includes approximately $5.5 billion for Paxlovid.
- Excluding Comirnaty and Paxlovid, Pfizer expects full-year 2024 operational revenue growth of 9% to 11%.
Headwinds
- Guidance does not assume completion of any business development transactions not completed as of September 29, 2024.
- Guidance anticipates an immaterial impact from recent and expected generic and biosimilar competition.
- Guidance reflects anticipated unfavorable impact of approximately $0.3 billion on revenues due to changes in foreign exchange rates.
- Guidance assumes no share repurchases in 2024.
- Guidance assumes the seasonal cadence of certain products and that Paxlovid results trend with infection rates.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
-0.3%
Avg return
Earnings day
-0.3%
Avg return
5 days after
+0.1%
Avg return
30 days after
50%
36 / 72 earnings
Positive
+8.1%
Q1 2024
Best reaction
-10.0%
Q2 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.2% | -2.5% | -2.3% | |
| Q4 2025 | -3.3% | +2.1% | -0.2% | |
| Q3 2025 | -1.5% | -0.9% | +4.2% | |
| Q1 2025 | +3.2% | +5.0% | +1.7% | |
| Q4 2024 | -1.3% | -1.8% | +0.2% | |
| Q3 2024 | -1.2% | -2.7% | -10.5% | |
| Q2 2024 | -0.6% | -0.9% | -6.5% | |
| Q1 2024 | +8.1% | +9.9% | +11.9% | |
| Q4 2023 | -1.5% | -2.0% | -3.3% | |
| Q3 2023 | -0.1% | +2.3% | -0.3% | |
| Q2 2023 | -2.0% | -2.9% | -1.9% | |
| Q1 2023 | -1.9% | -1.8% | -3.0% | |
| Q4 2022 | +1.0% | +1.2% | -6.7% | |
| Q3 2022 | +1.1% | +1.4% | +9.7% | |
| Q2 2022 | -2.8% | -4.4% | -9.9% | |
| Q1 2022 | +2.7% | +1.4% | +9.0% | |
| Q4 2021 | -3.3% | -4.6% | -7.5% | |
| Q3 2021 | +2.7% | +11.4% | +21.5% | |
| Q2 2021 | +1.6% | +4.4% | +10.7% | |
| Q1 2021 | +0.4% | -0.6% | -2.2% | |
| Q4 2020 | -2.7% | -2.5% | -4.5% | |
| Q3 2020 | -6.5% | -6.4% | +1.5% | |
| Q2 2020 | +4.6% | +2.5% | +0.9% | |
| Q1 2020 | -0.5% | -1.8% | -0.4% | |
| Q4 2019 | -6.4% | -7.3% | -15.1% | |
| Q3 2019 | +3.2% | +3.0% | +3.6% | |
| Q2 2019 | -10.0% | -11.8% | -18.6% | |
| Q1 2019 | +3.0% | +4.5% | +5.8% | |
| Q4 2018 | +5.2% | +8.5% | +9.7% | |
| Q3 2018 | -0.4% | -0.7% | +5.3% | |
| Q2 2018 | +4.3% | +5.1% | +7.5% | |
| Q1 2018 | -4.7% | -4.8% | -1.9% | |
| Q4 2017 | -5.1% | -6.2% | -8.7% | |
| Q3 2017 | +0.3% | +1.1% | +3.2% | |
| Q2 2017 | -0.7% | +1.4% | +2.3% | |
| Q1 2017 | -0.9% | -0.9% | -3.2% | |
| Q4 2016 | +1.1% | +2.5% | +10.2% | |
| Q3 2016 | -3.4% | -5.4% | -0.8% | |
| Q2 2016 | -5.4% | -5.0% | -7.0% | |
| Q1 2016 | +1.8% | — | — | |
| Q4 2015 | -1.6% | — | — | |
| Q3 2015 | +3.8% | — | — | |
| Q2 2015 | +4.1% | — | — | |
| Q1 2015 | -0.9% | — | — | |
| Q4 2014 | -2.6% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | -2.8% | — | — | |
| Q1 2014 | -4.3% | — | — | |
| Q4 2013 | +1.5% | — | — | |
| Q3 2013 | +0.6% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -5.0% | — | — | |
| Q4 2012 | +2.5% | — | — | |
| Q3 2012 | -1.3% | — | — | |
| Q2 2012 | +0.9% | — | — | |
| Q1 2012 | +0.9% | — | — | |
| Q4 2011 | -0.6% | — | — | |
| Q3 2011 | +3.4% | — | — | |
| Q2 2011 | +4.8% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2010 | +1.5% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q2 2010 | +0.5% | — | — | |
| Q1 2009 | -4.1% | — | — | |
| Q1 2010 | -1.1% | — | — | |
| Q4 2007 | +0.4% | — | — | |
| Q4 2009 | +0.4% | — | — | |
| Q3 2008 | +0.2% | — | — | |
| Q3 2009 | +0.2% | — | — | |
| Q4 2008 | +0.6% | — | — | |
| Q2 2008 | +0.6% | — | — | |
| Q2 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro